SCHEMBL3480412

SCHEMBL3480412

O=C(NCCOc1cc2cc(S(=O)(=O)NCP(=O)(O)O)sc2cc1OCCNC(=O)c1ccc(F)c(F)c1)c1ccc(F)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 3/20 0.35
HPGD P15428 2/20 0.35
MAPK1 P28482 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TP53 P04637 3/20 0.34
NPC1 O15118 4/20 0.34
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PKM P14618 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3480294 0.88 XDH (0.35) RAB9AKMT2AMAPK1TP53NPC1
SCHEMBL3480637 0.88 CNR2 (0.37) RAB9AKMT2AHPGDTP53NPC1
SCHEMBL3480229 0.88 NPY5R (0.39) RAB9AMAPTHPGDCYP1A2CYP2C19
SCHEMBL3931223 0.87 RAB9A (0.38) RAB9AKMT2AMAPTHPGDMAPK1
SCHEMBL3931225 0.87 MAPT (0.41) RAB9AKMT2AMAPTHPGDMAPK1
SCHEMBL3480271 0.87 RAB9A (0.43) RAB9AKMT2AHPGDNPC1SMN1; SMN2
SCHEMBL3480682 0.86 RAB9A (0.36) RAB9AKMT2AHPGDMAPK1NPC1
SCHEMBL12979418 0.85 TRPV4 (0.33) MAPT
SCHEMBL3480325 0.84 XDH (0.39) ALDH1A1
SCHEMBL3480053 0.84 XDH (0.39) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US claimed
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MGAM, BPGM, PPME1 RAB9A 1592/4885KMT2A 2187/4885MAPT 4576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.